Artificial bone 3D printing company Osteopore has received Therapeutic Goods Administration approval for sale of its craniofacial reconstruction products.
The TGA has added the Osteomesh, Osteoplug and Ostroplug-C range of 3D printed bioresorbale scaffolds that aid bone growth and healing to the Australian Register of Therapeutic Goods and they will also be included in the Prosthesis Listing in July.
The products are used a void fillers for regeneration for natural bone following neurological and craniofacial surgery.
Osteopore’s products have been previously used in Australia under the Special Access Scheme.
In 2017 the company’s technology was successfully used to regenerate a patient’s tibia after 36cm was removed due to infection.
Osteopore CEO Goh Khoon Seng said the approval opened up Australian markets for the company.
“Australia is a key market for the global expansion of our business, and we are excited to be able to build our revenue streams in this market.”
Subscribe to our free @AuManufacturing newsletter here.